Forward Progress in Molecular Markers for Prostate Cancer
Matthew R. Cooperberg, MD, MPH, argues biomarkers can persuade primary care physicians to increase patient screening of prostate cancer.
Read MoreSelect Page
Posted by Matthew R. Cooperberg, MD, MPH | Apr 2023
Matthew R. Cooperberg, MD, MPH, argues biomarkers can persuade primary care physicians to increase patient screening of prostate cancer.
Read MorePosted by Abhinav Sidana, MD, MPH | Apr 2023
Abhinav Sidana, MD, discusses candidate selection for focal therapy, including imaging/biopsy strategies and disease/patient characteristics.
Read MorePosted by Rana R. McKay, MD | Apr 2023
Rana R. McKay, MD, discusses patient selection and the treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC).
Read MorePosted by Sigrid V. Carlsson, MD, PhD, MPH | Apr 2023
Sigrid V. Carlsson, MD, PhD, MPH discusses prostate cancer screening, focusing on PSA screening, risk calculators, biomarkers, and MRI.
Read MorePosted by Edward Weber, MD | Apr 2023
This Commentary reviews the underlying biology of PARP inhibitors and data supporting olaparib plus abiraterone as first-line therapy for mCRPC.
Read More